glp 1 agonists and pancreatitis Risk of pancreatic cancer associated with GLP-1 receptor agonist therapy Pancreatitis risk from GLP1 use
Description
Jastreboff et al., NEJM, 2023
Modern GLP-1/GIP therapies are designed to work with your bodys natural metabolic signals, helping regulate appetite, improve insulin sensitivity, and support sustainable fat loss without the crash-and-burn cycle of traditional dieting
2021;43(1):112122.e1
Recent pharmacovigilance studies have attempted to quantify this association
An initial analysis of the FDA adverse event reporting system (FAERS) data demonstrated no consistent trends in DKA with SGLT2i use over time [39], however an alternative cohort study of 50,220 individuals with type 2 diabetes showed the highest risk of DKA shortly after SGLT2i initiation, which subsequently reduced with time [40]
This approach may benefit individuals with time constraints, though medical clearance is advisable for those with cardiovascular risk factors
